$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

$cpix Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024036529 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$9.086M	$9.849M
YoY Change	-9.92%	-9.55%
Cost Of Revenue	$1.323M	$1.711M
YoY Change	-25.07%	12.5%
Gross Profit	$7.763M	$8.138M
YoY Change	-6.7%	-13.13%
Gross Profit Margin	85.44%	82.63%
Selling, General & Admin	$7.073M	$7.006M
YoY Change	-0.2%	-0.52%
% of Gross Profit	91.11%	86.09%
Research & Development	$1.306M	$1.059M
YoY Change	-32.14%	-7.5%
% of Gross Profit	16.83%	13.02%
Depreciation & Amortization	$1.116M	$1.139M
YoY Change	-10.44%	-5.12%
% of Gross Profit	14.38%	14.0%
Operating Expenses	$8.379M	$8.065M
YoY Change	-7.02%	-1.49%
Operating Profit	-$1.694M	-$1.027M
YoY Change	-9.22%	-4591.4%
Interest Expense	$137.4K	$126.3K
YoY Change	24.79%	-34.41%
% of Operating Profit
Other Income/Expense, Net	$237.1K	$0.00
YoY Change	-71.15%	-100.0%
Pretax Income	-$1.526M	-$1.091M
YoY Change	44.42%	-225.56%
Income Tax	$11.44K	$11.44K
% Of Pretax Income
Net Earnings	-$1.544M	-$1.086M
YoY Change	47.15%	-224.47%
Net Earnings / Revenue	-16.99%	-11.02%
Basic Earnings Per Share	-$0.11	-$0.08
Diluted Earnings Per Share	-$0.11	-$0.08
COMMON SHARES
Basic Shares Outstanding	14.10M shares	14.19M shares
Diluted Shares Outstanding	14.05M shares	14.12M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.46M	$17.34M
YoY Change	-5.64%	-5.0%
Cash & Equivalents	$17.46M	$17.34M
Short-Term Investments
Other Short-Term Assets	$1.951M	$2.323M
YoY Change	-1.0%	1.97%
Inventory	$4.510M	$4.302M
Prepaid Expenses
Receivables	$11.31M	$11.62M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$35.24M	$35.58M
YoY Change	-15.64%	-18.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$312.0K	$337.1K
YoY Change	-17.33%	-12.3%
Goodwill	$914.0K	$914.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.830M	$2.994M
YoY Change	10.72%	14.84%
Total Long-Term Assets	$41.51M	$42.94M
YoY Change	-9.72%	-6.05%
TOTAL ASSETS
Total Short-Term Assets	$35.24M	$35.58M
Total Long-Term Assets	$41.51M	$42.94M
Total Assets	$76.75M	$78.52M
YoY Change	-12.54%	-12.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.06M	$12.51M
YoY Change	11.46%	14.63%
Accrued Expenses	$391.7K	$376.8K
YoY Change	17.17%	17.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.989M
YoY Change
Total Short-Term Liabilities	$31.09M	$24.76M
YoY Change	13.76%	-8.17%
LONG-TERM LIABILITIES
Long-Term Debt	$10.10M	$16.09M
YoY Change	-21.82%	22.39%
Other Long-Term Liabilities	$6.091M	$6.539M
YoY Change	-5.64%	-5.97%
Total Long-Term Liabilities	$6.091M	$6.539M
YoY Change	-5.64%	-5.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.09M	$24.76M
Total Long-Term Liabilities	$6.091M	$6.539M
Total Liabilities	$52.28M	$52.49M
YoY Change	0.35%	-0.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.06M	-$20.52M
YoY Change	97.11%	102.28%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.78M	$26.35M
YoY Change
Total Liabilities & Shareholders Equity	$76.75M	$78.52M
YoY Change	-12.54%	-12.15%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.544M	-$1.086M
YoY Change	47.15%	-224.47%
Depreciation, Depletion And Amortization	$1.116M	$1.139M
YoY Change	-10.44%	-5.12%
Cash From Operating Activities	$475.5K	-$855.7K
YoY Change	-61.55%	-116.34%
INVESTING ACTIVITIES
Capital Expenditures	$47.92K	$46.80K
YoY Change	-49.6%	-51.66%
Acquisitions
YoY Change
Other Investing Activities	$237.6K
YoY Change
Cash From Investing Activities	$189.6K	-$46.80K
YoY Change	-299.47%	-51.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-536.8K	-309.6K
YoY Change	-39.17%	-90.55%
NET CHANGE
Cash From Operating Activities	475.5K	-855.7K
Cash From Investing Activities	189.6K	-46.80K
Cash From Financing Activities	-536.8K	-309.6K
Net Change In Cash	128.3K	-1.212M
YoY Change	-50.44%	-165.06%
FREE CASH FLOW
Cash From Operating Activities	$475.5K	-$855.7K
Capital Expenditures	$47.92K	$46.80K
Free Cash Flow	$427.6K	-$902.5K
YoY Change	-62.54%	-117.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11871363	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13596528	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24756169	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27982249	usd
CY2024Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	16091592	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5100260	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5296247	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6538970	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6453566	usd
CY2024Q2	us-gaap	Liabilities Liabilities	52486991	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14121833	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14121833	shares
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20520036	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17488161	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10888877	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1710944	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1520774	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4248401	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4672075	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1059187	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1145038	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2757148	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2369883	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1099857	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1158248	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	10875537	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	10866018	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	12784144	usd
CY2023Q4	us-gaap	Liabilities Liabilities	52516206	usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	26348990	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	29603441	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-316806	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-343572	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26032184	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29259869	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78519175	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81776075	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9848849	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1026688	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	22859	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	61841	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	57061	usd
CY2024Q2	us-gaap	Other Income OtherIncome	0	usd
CY2023Q2	us-gaap	Other Income OtherIncome	981806	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	862154	usd
	us-gaap	Profit Loss ProfitLoss	-3005109	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-17025	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	349910	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18249086	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36048487	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14083183	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14083183	shares
CY2024Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	46869026	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	47091602	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	126347	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	192635	usd
	us-gaap	Interest Expense InterestExpense	244873	usd
	us-gaap	Interest Expense InterestExpense	378988	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1091194	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	869091	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2982224	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1048315	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11443	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6937	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22885	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13875	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-1102637	usd
	us-gaap	Profit Loss ProfitLoss	1034440	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10046	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	26766	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-29944	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1085612	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	872200	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3031875	usd
	us-gaap	Net Income Loss NetIncomeLoss	1064384	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14118091	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14393711	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14107852	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14376260	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14118091	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14554264	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14107852	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14570798	shares
	us-gaap	Profit Loss ProfitLoss	-3005109	usd
	us-gaap	Profit Loss ProfitLoss	1034440	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2290130	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2456590	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	570369	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	468359	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	150712	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	188034	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-442321	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-476606	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	8654	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	7809	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1861587	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-944925	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1243245	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	232110	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-424684	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-808699	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-429064	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1042792	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1925886	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	386614	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	85404	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-630813	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2992307	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3817152	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48799	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	179453	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	56191	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	91808	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104990	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-271261	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	22000000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	16000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	18692552	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	19051875	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	813478	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1652990	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	381851	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2112119	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5054775	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-985178	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1508884	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18321624	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19757970	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17336446	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35974006	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	90156	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	187961	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	172286	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36048487	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	97877	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	171616	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	862154	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36836902	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29259869	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	78754	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	246599	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1902472	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27189552	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27189552	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	71958	usd
CY2024Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	126689	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-1102637	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26032184	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1085612	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	872200	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14118091	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14393711	shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	160553	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14118091	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14554264	shares
	us-gaap	Net Income Loss NetIncomeLoss	-3031875	usd
	us-gaap	Net Income Loss NetIncomeLoss	1064384	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14107852	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14376260	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	194538	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14107852	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14570798	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	576517	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	413074	shares
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9848849	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10888877	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18346550	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20113515	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	100000	usd
CY2024Q2	us-gaap	Sublease Income SubleaseIncome	100000	usd
	us-gaap	Sublease Income SubleaseIncome	300000	usd
	us-gaap	Sublease Income SubleaseIncome	200000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	20000.00	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2024Q2	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	12684573	usd
CY2023Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	12619092	usd
CY2024Q2	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	185658	usd
CY2023Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	149701	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3300414	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4645098	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	16170646	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	17413891	usd
CY2024Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	11868487	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12804529	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	4302159	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4609362	usd
CY2024Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	11868487	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12804529	usd
CY2021Q4	cpix	Lessee Operating Lease Rent Increase LesseeOperatingLeaseRentIncrease	0.025
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y10M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0939
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0940
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6365790	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6674394	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	376780	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	348092	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5100260	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5296247	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5477040	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5644339	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	200000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	434255	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	836100	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	909911	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	934180	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	740791	usd
CY2024Q2	cpix	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4847401	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8702638	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3225598	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5477040	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	344418	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	226772	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	699482	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	501029	usd
CY2024Q2	us-gaap	Sublease Income SubleaseIncome	123230	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	130842	usd
	us-gaap	Sublease Income SubleaseIncome	278913	usd
	us-gaap	Sublease Income SubleaseIncome	245499	usd
CY2024Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	2600000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	3529	shares
CY2017Q4	cpix	Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities	100000000	usd
CY2024Q1	cpix	Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities	5800000	usd
CY2023Q3	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P3Y
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44100000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
cpix-20240630_cal.xml	Edgar Link	unprocessable
0001628280-24-036529-index-headers.html	Edgar Link	pending
0001628280-24-036529-index.html	Edgar Link	pending
0001628280-24-036529.txt	Edgar Link	pending
0001628280-24-036529-xbrl.zip	Edgar Link	pending
a2024q2-exhibit311.htm	Edgar Link	pending
a2024q2-exhibit312.htm	Edgar Link	pending
a2024q2-exhibit321.htm	Edgar Link	pending
cpix-20240630.htm	Edgar Link	pending
cpix-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
cpix-20240630_def.xml	Edgar Link	unprocessable
cpix-20240630_lab.xml	Edgar Link	unprocessable
cpix-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cpix-20240630_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2024 Q3 Form 10-Q Financial Statement

#000162828024036529 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2024 Q3 Form 10-Q Financial Statement

#000162828024036529 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix